In the setting of the rising morbidity of obesity, insulin resistance, and NAFLD, thyroid hormone analogues and metabolites present a promising avenue for the discovery of new, much needed pharmacologic agents. The gene discussed is TG; the disease is obesity due to melanocortin 4 receptor deficiency.